menu
    • menu
    [{"orgOrder":0,"company":"Active Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Tasquinimod","moa":"immunomodulators","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Active Biotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Active Biotech \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Active Biotech \/ Undisclosed"},{"orgOrder":0,"company":"Active Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Tasquinimod","moa":"||immunomodulators","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Active Biotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Active Biotech \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Active Biotech \/ Undisclosed"},{"orgOrder":0,"company":"Active Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Tasquinimod","moa":"immunomodulators","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Active Biotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Active Biotech \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Active Biotech \/ Undisclosed"},{"orgOrder":0,"company":"Active Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Tasquinimod","moa":"immunomodulators","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Active Biotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Active Biotech \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Active Biotech \/ Undisclosed"},{"orgOrder":0,"company":"Active Biotech","sponsor":"Oncode Institute","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Miscellaneous","year":"2022","type":"Licensing Agreement","leadProduct":"Tasquinimod","moa":"immunomodulators","graph1":"Oncology","graph2":"Preclinical","graph3":"Active Biotech","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Active Biotech \/ Oncode Institute","highestDevelopmentStatusID":"4","companyTruncated":"Active Biotech \/ Oncode Institute"},{"orgOrder":0,"company":"University of Pennsylvania","sponsor":"Active Biotech","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Tasquinimod","moa":"immunomodulators","graph1":"Oncology","graph2":"Phase I","graph3":"University of Pennsylvania","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"University of Pennsylvania \/ Active Biotech","highestDevelopmentStatusID":"6","companyTruncated":"University of Pennsylvania \/ Active Biotech"},{"orgOrder":0,"company":"Wistar Institute of Anatomy and Biology","sponsor":"Active Biotech","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Acquisition","leadProduct":"Tasquinimod","moa":"||immunomodulators","graph1":"Oncology","graph2":"Phase I","graph3":"Wistar Institute of Anatomy and Biology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Wistar Institute of Anatomy and Biology \/ Active Biotech","highestDevelopmentStatusID":"6","companyTruncated":"Wistar Institute of Anatomy and Biology \/ Active Biotech"},{"orgOrder":0,"company":"MD Anderson Cancer Center","sponsor":"Active Biotech","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Tasquinimod","moa":"immunomodulators","graph1":"Oncology","graph2":"Phase II","graph3":"MD Anderson Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MD Anderson Cancer Center \/ Active Biotech","highestDevelopmentStatusID":"8","companyTruncated":"MD Anderson Cancer Center \/ Active Biotech"}]

    Find Clinical Drug Pipeline Developments & Deals for Tasquinimod

    Menu

    Tasquinimod

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Wistar Institute of Anatomy and Biology

                            Country arrow
                            The Battery Show
                            Not Confirmed

                            Wistar Institute of Anatomy and Biology

                            Country arrow
                            The Battery Show
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tasquinimod,Ixazomib Citrate,Lenalidomide

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Active Biotech

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Active Biotech Acquires Exclusive Rights to Patents of Tasquinimod in Combination Therapy

                            Details : Under the terms of the agreement, Wistar grants Active Biotech a global exclusive license to develop and commercialize tasquinimod in combination therapy, as a treatment for multiple myeloma.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            May 22, 2024

                            Lead Product(s) : Tasquinimod,Ixazomib Citrate,Lenalidomide

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Active Biotech

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            MD Anderson Cancer Center

                            Country arrow
                            The Battery Show
                            Not Confirmed

                            MD Anderson Cancer Center

                            Country arrow
                            The Battery Show
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tasquinimod

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Active Biotech

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Open Label Phase 2 Study of Tasquinimod in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera M...

                            Details : Tasquinimod is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Primary Myelofibrosis.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            March 25, 2024

                            Lead Product(s) : Tasquinimod

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Active Biotech

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Active Biotech

                            Sweden arrow
                            The Battery Show
                            Not Confirmed

                            Active Biotech

                            Sweden arrow
                            The Battery Show
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tasquinimod

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : Oncode Institute

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Active Biotech Enters Into Global Patent License Agreement with Oncode Institute for Tasquinimod in Myelofibro...

                            Details : Under the terms of the agreement, Oncode Institute, a foundation under the laws of the Netherlands, acting on behalf of Erasmus Universiteit Medisch Centrum, grants a global exclusive license to develop and commercialize tasquinimod worldwide in MF to Ac...

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            February 09, 2022

                            Lead Product(s) : Tasquinimod

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : Oncode Institute

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Active Biotech

                            Sweden arrow
                            The Battery Show
                            Not Confirmed

                            Active Biotech

                            Sweden arrow
                            The Battery Show
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tasquinimod

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Preclinical Tasquinimod Data Presented at ASH 2021 Available on Active Biotech’s Website

                            Details : Preclinical data on drug tasquinimod, a small molecule immunomodulator Targets Immunosuppressive Myeloid Cells, Increases Osteogenesis and Has Direct Anti-Myeloma Effects by Inhibiting c-Myc Expression in Vitro and In Vivo.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            December 15, 2021

                            Lead Product(s) : Tasquinimod

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Active Biotech

                            Sweden arrow
                            The Battery Show
                            Not Confirmed

                            Active Biotech

                            Sweden arrow
                            The Battery Show
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tasquinimod,Ixazomib Citrate,Lenalidomide

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Active Biotech: Tasquinimod Clinical Development in Multiple Myeloma Advances Into Combination Therapy Followi...

                            Details : Tasquinimod is an oral immunomodulatory and anti-angiogenic investigational treatment, that affects the tumor’s ability to grow and metastasize. Tasquinimod is developed as a new immunomodulatory treatment for multiple myeloma.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            October 03, 2021

                            Lead Product(s) : Tasquinimod,Ixazomib Citrate,Lenalidomide

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Active Biotech

                            Sweden arrow
                            The Battery Show
                            Not Confirmed

                            Active Biotech

                            Sweden arrow
                            The Battery Show
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tasquinimod

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Active Biotech Announces First Patient Dosed in Phase 1b/2a Study of Tsquinimod Use in Treatment of Multiple M...

                            Details : The primary objective of the study is to establish the optimal dose and treatment schedule of tasquinimod when used as a single agent and in combination with IRd.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            August 03, 2020

                            Lead Product(s) : Tasquinimod

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            University of Pennsylvania

                            Country arrow
                            The Battery Show
                            Not Confirmed

                            University of Pennsylvania

                            Country arrow
                            The Battery Show
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tasquinimod

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Active Biotech

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Tasquinimod for the Treatment of Relapsed or Refractory Myeloma

                            Details : Tasquinimod is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Multiple Myeloma.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            May 28, 2020

                            Lead Product(s) : Tasquinimod

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Active Biotech

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Active Biotech

                            Sweden arrow
                            The Battery Show
                            Not Confirmed

                            Active Biotech

                            Sweden arrow
                            The Battery Show
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tasquinimod

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Active Biotech announces new direction

                            Details : Tasquinimod will be advanced in a new academic partnership, as an immunomodulatory product with a novel mechanism of action, for the treatment of multiple myeloma.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            February 05, 2020

                            Lead Product(s) : Tasquinimod

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth